These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31688415)

  • 1. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    Perri T; Farhadian Y; Friedman E; Korach J
    Menopause; 2020 Jan; 27(1):82-87. PubMed ID: 31688415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
    Breda AS; Blaakær J
    Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
    Palaia I; Caruso G; Di Donato V; Turetta C; Savarese A; Perniola G; Gallo R; Giannini A; Salutari V; Bogani G; Tomao F; Giannarelli D; Gentile G; Musella A; Muzii L; Pignata S;
    J Gynecol Oncol; 2024 May; 35(3):e70. PubMed ID: 38497108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
    Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Chiariello G; Lepera A; Cazzato G; Cascardi E; Damiani GR; Cicinelli E; Cormio G
    Hormones (Athens); 2023 Mar; 22(1):19-23. PubMed ID: 36637775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
    Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
    Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
    Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.
    DiSilvestro JB; Haddad J; Robison K; Beffa L; Laprise J; Scalia-Wilbur J; Raker C; Clark M; Lokich E; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
    Menopause; 2023 Jul; 30(7):732-737. PubMed ID: 37192837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
    Birrer N; Chinchilla C; Del Carmen M; Dizon DS
    Am J Clin Oncol; 2018 Mar; 41(3):313-315. PubMed ID: 26840041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    Mejia-Gomez J; Gronwald J; Senter L; Karlan BY; Tung N; Wolfman W; Demsky R; Sun P; Narod SA; Kotsopoulos J;
    Menopause; 2020 Dec; 27(12):1396-1402. PubMed ID: 32796289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.